Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Analyst Ratings
Strong Buy
15 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IONS Stock 12 Month Forecast
Average Price Target
$61.83
▲(45.00% Upside)
| Highest Price Target$83.00 | Average Price Target$61.83 | Lowest Price Target$40.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
$55
Buy
28.99%
Upside
Reiterated
08/25/25
Ionis Pharmaceuticals: Buy Rating Driven by Anticipated Phase 3 Trial Results for OlezarsenWe frame our expectations for the pivotal Ph3 readouts (CORE & CORE2) of olezarsen in severe hypertriglyceridemia (SHTG). Results are expected in September, and we view the readout as a meaningful catalyst for the stock. SHTG is an indication with a high unmet need, a TAM of ~3M U.S. pts, and a potential $1B+ commercial opportunity. Our base-case scenario (50% POS) assumes 1) primary endpoint of % reduction in triglycerides is met and 2) positive trends on the acute pancreatitis key secondary endpoint on the readout. In this scenario, we estimate IONS shares have +25% upside potential on the readout. We model ~$1.3B in non-risk-adjusted peak U.S. revenue for olezarsen, which accounts for ~$16/sh in our $55 price target.
J.P. Morgan
$48→$49
Hold
14.92%
Upside
Reiterated
08/25/25
Piper Sandler
$62→$65
Buy
52.44%
Upside
Reiterated
08/22/25
TD Cowen
$59
Buy
38.37%
Upside
Reiterated
08/22/25
Citi
$65→$69
Buy
61.82%
Upside
Reiterated
08/22/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Wells Fargo
$77→$82
Buy
92.31%
Upside
Reiterated
08/22/25
Raymond James
$64
Buy
50.09%
Upside
Reiterated
08/22/25
Leerink Partners
$56
Buy
31.33%
Upside
Reiterated
08/22/25
H.C. Wainwright
$65→$70
Buy
64.17%
Upside
Reiterated
08/22/25
William Blair
―
Buy
―
Reiterated
08/21/25
Bank of America Securities
$63→$64
Buy
50.09%
Upside
Reiterated
08/21/25
Stifel Nicolaus
$38→$43
Hold
0.84%
Upside
Reiterated
08/21/25
Barclays
$57→$58
Buy
36.02%
Upside
Reiterated
08/21/25
Morgan Stanley
$62
Buy
45.40%
Upside
Reiterated
08/21/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
$55
Buy
28.99%
Upside
Reiterated
08/25/25
Ionis Pharmaceuticals: Buy Rating Driven by Anticipated Phase 3 Trial Results for OlezarsenWe frame our expectations for the pivotal Ph3 readouts (CORE & CORE2) of olezarsen in severe hypertriglyceridemia (SHTG). Results are expected in September, and we view the readout as a meaningful catalyst for the stock. SHTG is an indication with a high unmet need, a TAM of ~3M U.S. pts, and a potential $1B+ commercial opportunity. Our base-case scenario (50% POS) assumes 1) primary endpoint of % reduction in triglycerides is met and 2) positive trends on the acute pancreatitis key secondary endpoint on the readout. In this scenario, we estimate IONS shares have +25% upside potential on the readout. We model ~$1.3B in non-risk-adjusted peak U.S. revenue for olezarsen, which accounts for ~$16/sh in our $55 price target.
J.P. Morgan
$48→$49
Hold
14.92%
Upside
Reiterated
08/25/25
Piper Sandler
$62→$65
Buy
52.44%
Upside
Reiterated
08/22/25
TD Cowen
$59
Buy
38.37%
Upside
Reiterated
08/22/25
Citi
$65→$69
Buy
61.82%
Upside
Reiterated
08/22/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Wells Fargo
$77→$82
Buy
92.31%
Upside
Reiterated
08/22/25
Raymond James
$64
Buy
50.09%
Upside
Reiterated
08/22/25
Leerink Partners
$56
Buy
31.33%
Upside
Reiterated
08/22/25
H.C. Wainwright
$65→$70
Buy
64.17%
Upside
Reiterated
08/22/25
William Blair
―
Buy
―
Reiterated
08/21/25
Bank of America Securities
$63→$64
Buy
50.09%
Upside
Reiterated
08/21/25
Stifel Nicolaus
$38→$43
Hold
0.84%
Upside
Reiterated
08/21/25
Barclays
$57→$58
Buy
36.02%
Upside
Reiterated
08/21/25
Morgan Stanley
$62
Buy
45.40%
Upside
Reiterated
08/21/25
Best Analysts Covering Ionis Pharmaceuticals
1 Month
xxx
Success Rate
12/20 ratings generated profit
Average Return
+2.02%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.02% per trade.
3 Months
xxx
Success Rate
19/33 ratings generated profit
Average Return
+3.54%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.58% of your transactions generating a profit, with an average return of +3.54% per trade.
1 Year
Success Rate
14/20 ratings generated profit
Average Return
+15.89%
reiterated a buy rating 12 days ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +15.89% per trade.
2 Years
xxx
Success Rate
26/33 ratings generated profit
Average Return
+11.31%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.79% of your transactions generating a profit, with an average return of +11.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IONS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
26
25
24
13
12
Buy
3
6
8
16
24
Hold
11
18
18
21
17
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
49
50
50
53
Each month's total comprises the sum of three months' worth of ratings.
IONS Financial Forecast
IONS Stock Forecast FAQ
What is IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 61.83.
What is IONS’s upside potential, based on the analysts’ average price target?
Ionis Pharmaceuticals has 45.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IONS a Buy, Sell or Hold?
Ionis Pharmaceuticals has a consensus rating of Strong Buy which is based on 15 buy ratings, 5 hold ratings and 0 sell ratings.
What is Ionis Pharmaceuticals’s price target?
The average price target for Ionis Pharmaceuticals is 61.83. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $83.00 ,the lowest forecast is $40.00. The average price target represents 45.00% Increase from the current price of $42.64.
The highest analyst price target is $83.00 ,the lowest forecast is $40.00. The average price target represents 45.00% Increase from the current price of $42.64.
What do analysts say about Ionis Pharmaceuticals?
Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of IONS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.